Home > Healthcare > Pharmaceuticals > Drug Delivery > Oral Transmucosal Drugs Market

Oral Transmucosal Drugs Market Trends

Report ID: GMI8477
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Oral Transmucosal Drugs Market Trends

Advancements in drug delivery technologies have revolutionized the field of medicine, offering more efficient and targeted ways to administer medications.

PLGA (poly lactic-co-glycolic acid) enhancers in implantable drug delivery systems (IDDS), represent a novel drug delivery systems technology, offering enhanced drug delivery capabilities. PLGA/PEG blend microparticles have been developed to serve as delivery enhancers in implantable drug delivery systems. These microparticles enable the controlled and sustained release of therapeutic agents, enhancing the efficacy and precision of drug delivery within the body, as a result increases the demand of oral transmucosal drugs.
Additionally, needle-free drug delivery technologies are gaining traction, offering alternatives to traditional injections. Companies like PharmaJet and NovaXS are pioneering needle-free systems for vaccine and therapeutic delivery. For instance, the Biojector 2000 is a professional-grade needle-free injection system designed for healthcare providers, capable of delivering intramuscular, subcutaneous, and intradermal injections. Such technological advancements are gaining the attention of healthcare professionals resulting in its increasing demand in the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market Size for oral transmucosal drugs was worth around USD 34.3 billion in 2023 and is set to record around 6.7% CAGR from 2024-2032 driven by the increasing prevalence of chronic diseases coupled with the rising demand for oral transmucosal drugs.

Oral transmucosal drugs industry share from the tablets segment is anticipated to generate USD 30.1 billion by 2032 owing to the convenience and ease of administration offered by tablets contributing significantly to improved patient compliance.

North America market accounted for USD 13.5 billion in 2023 and is poised to grow at a notable rate from 2024-2032 owing to the increasing prevalence of diabetes in North America.

Some of the leading companies engaged in the industry are Aquestive Therapeutics, Inc, C.L.Pharm Co., Ltd., Cure Pharmaceutical., IntelGenx Technologies Corp, Jazz Pharmaceuticals, plc., NAL Pharma, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Limited., and ZIM Laboratories Limited.